FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036

Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2 monoclonal antibodies, like trastuzumab or pertuzumab, and ATP active site in...

Descripción completa

Detalles Bibliográficos
Autores principales: Angus, Steven P., Stuhlmiller, Timothy J., Mehta, Gaurav, Bevill, Samantha M., Goulet, Daniel R., Olivares-Quintero, J. Felix, East, Michael P., Tanioka, Maki, Zawistowski, Jon S., Singh, Darshan, Sciaky, Noah, Chen, Xin, He, Xiaping, Rashid, Naim U., Chollet-Hinton, Lynn, Fan, Cheng, Soloway, Matthew G., Spears, Patricia A., Jefferys, Stuart, Parker, Joel S., Gallagher, Kristalyn K., Forero-Torres, Andres, Krop, Ian E., Thompson, Alastair M., Murthy, Rashmi, Gatza, Michael L., Perou, Charles M., Earp, H. Shelton, Carey, Lisa A., Johnson, Gary L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115531/
https://www.ncbi.nlm.nih.gov/pubmed/33980863
http://dx.doi.org/10.1038/s41523-021-00258-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115531/
https://www.ncbi.nlm.nih.gov/pubmed/33980863
http://dx.doi.org/10.1038/s41523-021-00258-0

Ejemplares similares